Using the blood protein vasorin to distinguish septic shock from other shocks

Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock

This project will test whether measuring vasorin in blood can tell adults in the ICU with septic shock apart from those with non-septic shock.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 144 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Centre Hospitalier Universitaire, Amiens (other)
• Locations: 1 site (Amiens)
• Trial ID: NCT07203833 on ClinicalTrials.gov

What this trial studies

Septic shock is a life-threatening form of infection for which earlier and more specific biomarkers are needed. The study will enroll adults admitted within 24 hours to the CHU Amiens‑Picardie ICU and collect blood samples to measure plasma vasorin concentrations. Participants are divided into two groups: septic shock (fever with suspected or documented infection, vasopressors and lactate ≥2 mmol/L) and non‑septic shock (no fever or suspected infection, vasopressors and lactate ≥2 mmol/L). Investigators will compare vasorin levels between groups and explore its potential diagnostic and prognostic value compared with existing markers like procalcitonin.

Who should consider this trial

Good fit: Adults (18+) admitted to the CHU Amiens‑Picardie ICU within 24 hours who require vasopressors for shock with lactate ≥2 mmol/L and meet criteria for either septic (fever and suspected/documented infection) or non‑septic (no fever, no suspected infection) shock.

Not a fit: Pregnant people, patients admitted more than 24 hours earlier, those without vasopressor‑dependent shock or with lactate <2 mmol/L, and patients treated outside CHU Amiens‑Picardie are not eligible and would not benefit from participation.

Why it matters

Potential benefit: If successful, vasorin measurement could enable faster, more accurate diagnosis of septic shock and help avoid unnecessary antibiotic treatment.

How similar studies have performed: Preclinical laboratory work links vasorin to septic shock, but clinical application of vasorin as a diagnostic biomarker is novel and not yet proven in larger patient cohorts.

Eligibility criteria

Inclusion Criteria:

* Adults over 18 years.
* Patients admitted for less than 24 hours in intensive care unit of the CHU Amiens Picardie.
* Group 1: patients with septic shock defined by sepsis with 2 mmol/l Lactates, requiring vasopressors to maintain mean blood pressure at 65 mmHg (despite adequate vascular filling) in the presence of fever (T°\>38.3) with a documented or suspected infection
* Group 2: patients with a shock defined by arterial hypotension requiring the use of vasopressors with 2 mmol/l Lactates but without suspected infection and apyrexie (T°\<38°). For example: vasoplegia post cardiac surgery with CBP or cardiogenic shock or hemorrhagic shock

Exclusion Criteria:

* Pregnant women
* Group 1 : No evidence of suspected or documented infection
* Group 2 : Presence of fever and/or suspected infection

Where this trial is running

Amiens

• CHU Amiens-Picardie — Amiens, France (RECRUITING)

Study contacts

• Study coordinator: Julien Maizel, Pr

Conditions: Vasorin, Septic Shock, Shock, Biomarker, Infection, Septic shock, vasorin